Drug Profile


Alternative Names: CRD5

Latest Information Update: 07 Jan 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Liponex
  • Developer Liponex; University of Ottawa Heart Institute
  • Class Antihyperlipidaemics
  • Mechanism of Action Apolipoprotein A I stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Dyslipidaemias

Most Recent Events

  • 20 Jul 2007 CRD 5 is available for licensing worldwide (
  • 18 Jul 2007 Preclinical trials in Dyslipidaemias in Canada (PO)
  • 13 Apr 2007 Results from a phase I/II clinical trial in patients with Dyslipidaemia added to the adverse events and Hyperlipidaemia therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top